Abstract
Of the many approaches evaluated to treat the symptoms of Alzheimer’s disease (AD), only cholinesterase inhibition has produced positive results. The clinical usefulness of the acetylcholinesterase inhibitors (AChEIs) has been limited by either an extremely short or excessively long half-life, hepatotoxicity, excessive peripheral cholinergic side effects, and the potential for drug-drug interactions. To obtain greater (maximum) therapeutic benefit, newer AChEIs that circumvent these problems must be developed. SDZ ENA 713 (ENA 713), a carbamate derivative, is a novel compound that appears to meet the criteria for an ideal AChEI. It is currently in late stages of clinical development worldwide.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Enz A, Amstutz R, Hofmann A, Gmelin G and Kelly PH (1990): ENA 713, an acetylcholinesterase-inhibitor with preference for central activity: animal studies. In: Basic, Clinical and Therapeutic Aspects of Alzheimer’s and Parkinson’s diseases. Nagaatsu T, Fischer A and Yoshida M, New York: Plenum Press, pp.425–428.
Enz A, Amstutz R, Boddeke H, Gmelin G and Malanowski J (1993): Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer’s desease. Progr Brain Res. 98:431–438.
Sramek J J, Anand R, Wardle TS, Irwin P, Hartman RD and Cutler NR (1996): Safety/tolerability trial of SDZENA713 in patients with probable Alzheimer’s disease. Life Sciences 58:1201–1207.
SDZENA 713 Investigator’s Brochure (1994): On file at Sandoz Pharmaceuticals Corp.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Birkhäuser Boston
About this chapter
Cite this chapter
Anand, R., Hartman, R.D., Hayes, P.E., Gharabawi, M. (1997). An Overview of the Development of SDZ ENA 713, A Brain Selective Cholinesterase Inhibitor. In: Becker, R.E., Giacobini, E., Barton, J.M., Brown, M. (eds) Alzheimer Disease. Advances in Alzheimer Disease Therapy. Birkhäuser Boston. https://doi.org/10.1007/978-1-4612-4116-4_35
Download citation
DOI: https://doi.org/10.1007/978-1-4612-4116-4_35
Publisher Name: Birkhäuser Boston
Print ISBN: 978-1-4612-8660-8
Online ISBN: 978-1-4612-4116-4
eBook Packages: Springer Book Archive